Implantable cardioverter–defibrillator in hypertrophic cardiomyopathy

Figure 1.. Age at the time of implantation of a defibrillator in 128 patients with hypertrophic cardiomyopathy who were judged to be at high risk for sudden death.

Figure 2.. Estimated cumulative rates of first appropriate discharges, calculated separately for the 85 patients with defibrillators for primary prevention and the 43 patients with defibrillators for secondary prevention.

Figure 3.. Cumulative rates for first appropriate implantable defibrillator intervention in patients with 1, 2, or 3 or more risk factors who had received devices for primary prevention.

Figure 4.. Life-years gained and survival curves. Number of lifeyears gained by device implantation is equal to area between Kaplan-Meier survival curves. As follow-up time increases, more area is revealed.

Figure 5.. Kaplan–Meier curve for shock-free survival in patients after alcohol septal ablation.

Figure 6.. Forest plots and pooled estimates of (aborted) SCD rates after alcohol septal ablation and surgical myectomy, including ICD shocks.

Figure 7.. Recommendations on prevention of sudden cardiac death.

Figure 8.. Types of heart disease prompting implantation (first implantations, sole diagnosis).

Figure 9..

Figure 10.. Patient age at defibrillator implantation. Shown for 224 pediatric patients with hypertrophic cardiomyopathy judged at high risk for sudden death who underwent implantation for primary or secondary prevention

Figure 11.. ICD intervention rates. Cumulative rates for first appropriate implantable cardioverter-defibrillator (ICD) intervention, shown separately for patients who underwent implantation for primary (n = 188) or secondary (n = 36) prevention. The rate of first appropriate ICD shock for secondary prevention exceeded that for primary prevention by 4-fold.

Figure 12.. Number of sudden death risk factors and ICD interventions.